Nanomaterial-based blood-brain-barrier (BBB) crossing strategies

Xie, Jianping; Shen, Zheyu; Anraku, Yasutaka; Kataoka, Kazunori; Chen, Xiaoyuan

doi:10.1016/j.biomaterials.2019.119491

Cited by 365 publications

(275 citation statements)

References 223 publications

Supporting

Mentioning

274

Contrasting

Order By: Relevance

“…[ 4 ] It is reported that nearly 98% of small‐molecule drugs or contrast agents and most macromolecular drugs are routinely excluded from the brain, which makes the treatment and imaging of brain tumors extremely difficult. [ 5,6 ] Although the tight junctions of BBB at the late stage of brain tumors are disrupted to permit drug penetration into brain, the drug concentration in tumor sites is not sufficient to reach the therapeutic level. [ 7 ] More importantly, the treatment of the early stage of brain tumors is more challenging due to the presence of almost intact BBB.…”

Section: Introductionmentioning

confidence: 99%

“…So far, some drug delivery strategies have been proposed for the transportation of cargos crossing BBB to enter the CNS, such as adsorptive‐mediated transcytosis (AMT), carrier‐mediated transport (CMT), and receptor‐mediated transcytosis (RMT). [ 6,9 ] Nanoparticles conjugating a positively charged moiety, such as a cell penetrating peptide (CPP), can contact with the membrane surface of BBB (with negative charge) to traverse the BBB by AMT. [ 5,10 ] But the ability of such nanoparticles to traverse the BBB is relatively low because of limited affinity, lack of selectivity, and easy immune clearance.…”

Section: Introductionmentioning

confidence: 99%

“…[ 12,14–16 ] However, the less than 1.0% of the brain accumulation rate of these nanoparticles cannot meet the requirements of clinical use, which is due to the low efficiency of ligand upload on nanoparticles, weak binding ability with receptors, and the competition of high concentration of endogenous ligands in the blood. [ 5,6 ] Therefore, it is still challenging to develop a strategy to endow nanoparticles with essential functions such as BBB‐crossing ability, high tumor accumulation, and immune escape for the treatment of brain diseases.…”

Section: Introductionmentioning

confidence: 99%

“…[1] Despite the tremendous efforts made in the past few years, treatments and diagnoses of GBM competition of high concentration of endogenous ligands in the blood. [5,6] Therefore, it is still challenging to develop a strategy to endow nanoparticles with essential functions such as BBB-crossing ability, high tumor accumulation, and immune escape for the treatment of brain diseases.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Camouflaging Nanoparticles with Brain Metastatic Tumor Cell Membranes: A New Strategy to Traverse Blood–Brain Barrier for Imaging and Therapy of Brain Tumors

Wang

et al. 2020

Adv Funct Materials

152

120

View full text Add to dashboard Cite

Glioblastoma multiforme is one of the most fatal intracranial tumors with no effective treatment. The drug concentration in tumor sites is usually insufficient to reach therapeutic levels, due to poor blood–brain‐barrier (BBB) permeability and short biological half‐life. Inspired by the proneness of those malignant tumors to brain metastasis, a brain metastatic tumor cell membrane‐coated nanocarrier with core–shell structure is constructed to cross BBB for imaging and photothermal therapy of early brain tumors. The cell membranes as the shell are extracted from different metastatic tumor cells, which endow the nanoparticles with BBB‐crossing ability and long circulation. Indocyanine green (ICG)‐loaded polymeric nanoparticle as the core allows fluorescence imaging and phototherapy of brain tumors. The as‐prepared biomimetic nanoparticles display superb BBB penetration and effective suppression of tumor growth. These findings suggest the biomimetic nanotechnology provides a new insight for the design of BBB‐crossing nanomaterials and is promising to treat brain diseases.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Camouflaging Nanoparticles with Brain Metastatic Tumor Cell Membranes: A New Strategy to Traverse Blood–Brain Barrier for Imaging and Therapy of Brain Tumors

Wang

et al. 2020

Adv Funct Materials

152

120

View full text Add to dashboard Cite

show abstract

“…Discovering new methods to treat diseases is becoming increasingly complicated because of the numerous natural biological barriers in our bodies such as opsonization by proteins in the blood, first-pass clearance organs, and the immune response [1,2]. The difficulty of overcoming these barriers to create a cure is exponentially increased when trying to deliver pharmaceutics across the blood-brain barrier (BBB) [3,4]. This is due to the brains increased security including tight junctions, low molecule diffusion rates, efflux transporters, and difficulty in reaching sufficient drug exposure in the brain compartment [5].…”

Section: Introductionmentioning

confidence: 99%

PLGA-PEG-ANG-2 Nanoparticles for Blood–Brain Barrier Crossing: Proof-of-Concept Study

et al. 2020

View full text Add to dashboard Cite

The treatment of diseases that affect the central nervous system (CNS) represents a great research challenge due to the restriction imposed by the blood–brain barrier (BBB) to allow the passage of drugs into the brain. However, the use of modified nanomedicines engineered with different ligands that can be recognized by receptors expressed in the BBB offers a favorable alternative for this purpose. In this work, a BBB-penetrating peptide, angiopep-2 (Ang–2), was conjugated to poly(lactic-co-glycolic acid) (PLGA)-based nanoparticles through pre- and post-formulation strategies. Then, their ability to cross the BBB was qualitatively assessed on an animal model. Proof-of-concept studies with fluorescent and confocal microscopy studies highlighted that the brain-targeted PLGA nanoparticles were able to cross the BBB and accumulated in neuronal cells, thus showing a promising brain drug delivery system.

show abstract

Nanobiomimetic Medicine

Chang

Dong

Huang

et al. 2022

Adv Funct Materials

View full text Add to dashboard Cite

The application of nanotechnology in medicine aims at developing the precise theranostics of diseases by leveraging the extraordinary effects of engineered nanomedicines, materdicine, and biomaterials. However, finely controlling the biological behavior of nanomaterials in the complex living systems remains a great challenge in terms of accuracy and intelligence. Inspired by nature, biomimetics has become an attractive strategy based on the highly ordered natural biological structure for the development of clinically valuable materials and technologies, arising from the superior bioavailability. The rapid development of biomimetics in nanomedical applications prompts the authors to propose the concept of “nanobiomimetic medicine”, which is a considerable subdiscipline in nanomedicine and materdicine that applies the concept and strategies of biomimetics to facilitate and promote the disease theranostics. Herein, the authors aim to furnish a state‐of‐the‐art review on the latest progress in the field of nanobiomimetic medicine. The design strategies, structural features and biological properties of biomimetic materials are initially introduced to reveal the inherent bionic mechanism and the potential structure‐function relationships. Furthermore, advances with respect to the applications of diverse biomimetic materials are comprehensively summarized. Finally, the current challenges and future direction of nanobiomimetic medicine are discussed and prospected in order to stimulate more biomimetic fundamental and technological breakthroughs in nanomedicine.

show abstract

Nanomaterial-based blood-brain-barrier (BBB) crossing strategies

Cited by 365 publications

References 223 publications

Camouflaging Nanoparticles with Brain Metastatic Tumor Cell Membranes: A New Strategy to Traverse Blood–Brain Barrier for Imaging and Therapy of Brain Tumors

Camouflaging Nanoparticles with Brain Metastatic Tumor Cell Membranes: A New Strategy to Traverse Blood–Brain Barrier for Imaging and Therapy of Brain Tumors

PLGA-PEG-ANG-2 Nanoparticles for Blood–Brain Barrier Crossing: Proof-of-Concept Study

Nanobiomimetic Medicine

Contact Info

Product

Resources

About